Morepen Laboratories Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 26,42,596 shares,. Its Average Traded Price (ATP) is ₹98.21, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 226 @ ₹99.64.
Morepen Laboratories has an upper circuit limit of ₹104.62 and a lower circuit limit of ₹94.66. The total value traded stands at ₹25.95 CR, and the delivery percentage for the day is 0%.
The stock is currently traded with a market lot size of 1. Morepen Laboratories also offers a dividend yield of 0.2%.
Morepen Laboratories Share Price Chart
Morepen Laboratories Share Key Metrics
Volume
26.43 L
Market Cap
5459.81 CR
LTQ@LTP
226@99.64
ATP
98.21
Var Margin
100 %
Circuit Range
94.66-104.62
Delivery %
0 %
Value
25.95 CR
ASM/GSM
No
Market Lot
1
Morepen Laboratories Resistance and Support
Pivot 96.07
Resistance
First Resistance
98.14
Second Resistance
101.37
Third Resistance
103.44
Support
First Support
92.84
Second Support
90.77
Third Support
87.54
Morepen Laboratories Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Morepen Laboratories Corporate Actions
| Date | Agenda |
|---|---|
| 2026-10-27 | Quarterly Results |
Morepen Laboratories News
Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Credit Rating
Morepen Laboratories has received a credit rating upgrade for its bank facilities. Infomerics Valuation and Rating Limited upgraded the rating to IVR A/ Stable on 13 November 2026.
Nov 14 2026 11:38:01
Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Morepen Laboratories launched its first prescription generic product, Desloratadine Tablets USP, in the US market through Morepen Bio Inc. The company also submitted its first ANDA to the US FDA for Sitagliptin Phosphate Tablets, expanding its formulation and regulatory capabilities.
Nov 09 2026 08:54:06
Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Morepen reported Q2 FY27 revenue of Rs.755 crore (up 81% YoY) and net profit of Rs.89 crore (up 117% YoY). The growth was driven by scale-up in CDMO commercial supplies and strong Medical Devices performance, alongside capacity expansion to 614 KL.
Oct 27 2026 13:39:57
Morepen Laboratories Ltd - 500288 - Board Meeting Intimation for Q-2 FY27 Financial Results
Morepen Laboratories announced a board meeting scheduled for 27 Oct 2026. The board will consider and approve the financial results for the quarter ended 30 Sep 2026.
Oct 22 2026 18:31:13
Morepen Laboratories Management
| Name | Position |
|---|---|
| Sushil Suri | Chairman & Managing Director |
| Sanjay Suri | Whole Time Director |
Morepen Laboratories Similar Stocks
FDC Ltd.
372.10
-18.30 (4.69%)
Nephrocare Health Services Ltd.
651.05
28.40 (4.56%)
Innova Captab Ltd.
1172.40
9.60 (0.83%)
IOL Chemicals And Pharmaceuticals Ltd.
201.63
-3.45 (1.68%)
Senores Pharmaceuticals Ltd.
1174.60
-42.40 (3.48%)
Orchid Pharma Ltd.
884.40
26.60 (3.10%)
Supriya Lifescience Ltd.
632.10
-9.95 (1.55%)
Sahajanand Medical Technologies Ltd.
533.95
29.30 (5.81%)
Artemis Medicare Services Ltd.
321.80
5.05 (1.59%)
Morepen Laboratories FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in MOREPENLAB
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC
Or Download Choice FinX App
Invest in MOREPENLAB
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade